logo
Plus   Neg
Share
Email

Riverbed Technology Q4 Profit Declines On Higher Acquisition Costs; Stock Down

Riverbed Technology Inc. (RVBD) reported that its fourth-quarter net income declined to $4.78 million or $0.03 per share, from $20.15 million or $0.12 per share in the same quarter last year. Acquisition-related costs for the quarter rose to $13.23 million from $1.09 million in the year ago quarter.

Non-GAAP net income for the quarter was $46.46 million or $0.29 per share, compared to $41.11 million or $0.25 per share in the same quarter last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.29 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter rose to $237.38 million from $202.84 million in the prior year quarter. Thirty one analysts had consensus revenue estimate of $234.77million for the quarter.

In December 2012, Riverbed Technology announced that it closed its acquisition of OPNET Technologies Inc.

In October 2012, Riverbed Technology had entered into a definitive agreement to acquire OPNET Technologies, a provider of solutions for application and network performance management, for $43 per share in cash and stock.

RVBD closed Thursday's regular trading at $20.10, down $0.21 or 1.03%. In the after-hours, the stock is further down $1.55 or 7.71%.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT